Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: - Trial NCT01030770
Access comprehensive clinical trial information for NCT01030770 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by King's College Hospital NHS Trust and is currently Completed. The study focuses on Diabetes Complications. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
King's College Hospital NHS Trust
Timeline & Enrollment
Early Phase 1
Jul 01, 2010
May 01, 2016
Primary Outcome
Number of patients requiring pars plana vitrectomy at week 7.
Summary
This study will enrol patients with diabetes who have already elected to undergo pars plana
 vitrectomy (eye surgery) to remove persistent vitreous haemorrhage (a complication of severe
 diabetic eye disease in which blood fills the inner cavity of the eye, obscuring the vision
 and preventing treatment to stop the bleeding). Those in the treatment arm will have an
 intravitreal injection of ranibizumab (Lucentis) at the same dose used for the treatment of
 neovascular (wet) age-related macular degeneration (a disease that has some features in
 common with diabetic eye disease).
 
 It is hypothesised that this will promote clearance of the vitreous haemorrhage and that
 this, in turn, may mean that some patients do not need to proceed to vitrectomy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01030770
Non-Device Trial